Newsroom

Articles
SMS AFYA-YETU

Interview with Natalie Roberts : COVID-19 Alert and SMS Afia Yetu projects

Natalie Roberts is the director of studies at Crash and program manager at the MSF Foundation. During the first wave of the COVID-19 pandemic, she was involved in the implementation of two digital health applications.

Here she discusses the field of digital health and the challenge that COVID represented in the research on these issues. In this interview, we discover the needs behind the "Alerte-Niger" and "SMS Afia Yetu" projects, the stages of their development, but also the obstacles encountered by the MSF teams (the health context, relations with partners, preconceived ideas about the population).

Read more

Headline

Antibiogo 3
Articles
Antibiogo

Antibiogo ISO 13485 Certified, a First for a Humanitarian Project

In 2025, the Antibiogo application is seeing wide deployment, extending beyond MSF field operations. After being adopted by all MSF laboratories in 2024, the tool has also been integrated by local health authorities in several countries: Burkina Faso, Comoros, Guinea, Liberia, Mali, Central African Republic, Democratic Republic of the Congo, and Benin. This expansion marks a new era for Antibiogo: scaling up.

At the same time, the project team continued efforts to reach the highest level of quality standards, culminating in obtaining ISO 13485 certification. This unprecedented level of requirement for an NGO project reflects the excellence of the management practices implemented for this medical device project, for which MSF Foundation is the legal manufacturer.

Read more

MSF Foundation in Video

More articles

News

More articles

Publications

  • Publications
    Étude Fièvre Jaune

    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

    Read more
  • Publications
    Étude Fièvre Jaune

    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

    Read more
More articles

Press Review

More articles
No news for now.